

**REMARKS/ARGUMENTS**

After entry of the amendment, claims 1-7 and 31-52 remain pending. Claims 1, 5 and 6 have been amended. Claims 2-4 and 7 have been withdrawn. Claims 8-30 have been canceled. Claims 31-52 have been added. Applicants reserve the right to pursue such claims in a continuation or divisional application.

**Sequence Listing**

Applicants believe that the preliminary amendment submitted on October 28, 2003 amended the specification to provide sequence identifiers for each nucleotide and amino acid sequence in the specification. Each sequence is believed to be listed in the paper and computer readable copy of the sequence listing, which were submitted with the preliminary amendment. Specifically, in response to the Examiner's inquiry regarding page 12 of the specification, page 5 of the preliminary amendment provides sequence identifiers for the sequences found on page 12.

**Restriction Requirement**

The Examiner has restricted prosecution of this application to one of fifteen groups of claims. Applicants elect Group I (claims 1, 5 and 6) without traverse. The pending claims have been amended to recite biological reagents capable of inhibiting transplant rejection, as it reads on the CTLA-4 protein.

The Commissioner is authorized to charge any fees or credit any overpayment to Deposit Account No. 11-0980.

Respectfully submitted,

  
\_\_\_\_\_  
Stephanie D. Adams, Ph.D.  
Patent Agent  
Reg. No. 47,378  
Tel.: (404) 572-4600  
Fax: (404) 572-5145

Date: April 12, 2005  
KING & SPALDING LLP  
191 Peachtree Street, 45<sup>th</sup> Floor  
Atlanta, Georgia 30303-1763